Copyright Reports & Markets. All rights reserved.

Global Enfortumab Vedotin‑ejfv Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Enfortumab Vedotin‑ejfv Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 100 mg
    • 1.3.3 300 mg
  • 1.4 Market Analysis by Combination Therapy
    • 1.4.1 Overview: Global Enfortumab Vedotin‑ejfv Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
    • 1.4.2 Enfortumab vedotin + Pembrolizumab
    • 1.4.3 Enfortumab vedotin + platinum-based chemotherapy
  • 1.5 Market Analysis by Sales Channel
    • 1.5.1 Overview: Global Enfortumab Vedotin‑ejfv Consumption Value by Sales Channel: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hospital
    • 1.5.3 Retail
    • 1.5.4 Online
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Enfortumab Vedotin‑ejfv Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Advanced Urothelial Cancer
    • 1.6.3 Advanced Medullary Thyroid Cancer (MTC)
    • 1.6.4 Others
  • 1.7 Global Enfortumab Vedotin‑ejfv Market Size & Forecast
    • 1.7.1 Global Enfortumab Vedotin‑ejfv Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Enfortumab Vedotin‑ejfv Sales Quantity (2021-2032)
    • 1.7.3 Global Enfortumab Vedotin‑ejfv Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Sanofi
    • 2.1.1 Sanofi Details
    • 2.1.2 Sanofi Major Business
    • 2.1.3 Sanofi Enfortumab Vedotin‑ejfv Product and Services
    • 2.1.4 Sanofi Enfortumab Vedotin‑ejfv Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Sanofi Recent Developments/Updates
  • 2.2 Manus Aktteva Biopharma LLP
    • 2.2.1 Manus Aktteva Biopharma LLP Details
    • 2.2.2 Manus Aktteva Biopharma LLP Major Business
    • 2.2.3 Manus Aktteva Biopharma LLP Enfortumab Vedotin‑ejfv Product and Services
    • 2.2.4 Manus Aktteva Biopharma LLP Enfortumab Vedotin‑ejfv Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Manus Aktteva Biopharma LLP Recent Developments/Updates
  • 2.3 Apicore Pharmaceuticals
    • 2.3.1 Apicore Pharmaceuticals Details
    • 2.3.2 Apicore Pharmaceuticals Major Business
    • 2.3.3 Apicore Pharmaceuticals Enfortumab Vedotin‑ejfv Product and Services
    • 2.3.4 Apicore Pharmaceuticals Enfortumab Vedotin‑ejfv Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Apicore Pharmaceuticals Recent Developments/Updates
  • 2.4 GLR Innovations
    • 2.4.1 GLR Innovations Details
    • 2.4.2 GLR Innovations Major Business
    • 2.4.3 GLR Innovations Enfortumab Vedotin‑ejfv Product and Services
    • 2.4.4 GLR Innovations Enfortumab Vedotin‑ejfv Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 GLR Innovations Recent Developments/Updates
  • 2.5 Archerchem Healthcare
    • 2.5.1 Archerchem Healthcare Details
    • 2.5.2 Archerchem Healthcare Major Business
    • 2.5.3 Archerchem Healthcare Enfortumab Vedotin‑ejfv Product and Services
    • 2.5.4 Archerchem Healthcare Enfortumab Vedotin‑ejfv Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Archerchem Healthcare Recent Developments/Updates
  • 2.6 CLEARSYNTH LABS
    • 2.6.1 CLEARSYNTH LABS Details
    • 2.6.2 CLEARSYNTH LABS Major Business
    • 2.6.3 CLEARSYNTH LABS Enfortumab Vedotin‑ejfv Product and Services
    • 2.6.4 CLEARSYNTH LABS Enfortumab Vedotin‑ejfv Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 CLEARSYNTH LABS Recent Developments/Updates
  • 2.7 SynZeal Research
    • 2.7.1 SynZeal Research Details
    • 2.7.2 SynZeal Research Major Business
    • 2.7.3 SynZeal Research Enfortumab Vedotin‑ejfv Product and Services
    • 2.7.4 SynZeal Research Enfortumab Vedotin‑ejfv Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 SynZeal Research Recent Developments/Updates

3 Competitive Environment: Enfortumab Vedotin‑ejfv by Manufacturer

  • 3.1 Global Enfortumab Vedotin‑ejfv Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Enfortumab Vedotin‑ejfv Revenue by Manufacturer (2021-2026)
  • 3.3 Global Enfortumab Vedotin‑ejfv Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Enfortumab Vedotin‑ejfv by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Enfortumab Vedotin‑ejfv Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Enfortumab Vedotin‑ejfv Manufacturer Market Share in 2025
  • 3.5 Enfortumab Vedotin‑ejfv Market: Overall Company Footprint Analysis
    • 3.5.1 Enfortumab Vedotin‑ejfv Market: Region Footprint
    • 3.5.2 Enfortumab Vedotin‑ejfv Market: Company Product Type Footprint
    • 3.5.3 Enfortumab Vedotin‑ejfv Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Enfortumab Vedotin‑ejfv Market Size by Region
    • 4.1.1 Global Enfortumab Vedotin‑ejfv Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Enfortumab Vedotin‑ejfv Consumption Value by Region (2021-2032)
    • 4.1.3 Global Enfortumab Vedotin‑ejfv Average Price by Region (2021-2032)
  • 4.2 North America Enfortumab Vedotin‑ejfv Consumption Value (2021-2032)
  • 4.3 Europe Enfortumab Vedotin‑ejfv Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Enfortumab Vedotin‑ejfv Consumption Value (2021-2032)
  • 4.5 South America Enfortumab Vedotin‑ejfv Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Enfortumab Vedotin‑ejfv Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Enfortumab Vedotin‑ejfv Sales Quantity by Type (2021-2032)
  • 5.2 Global Enfortumab Vedotin‑ejfv Consumption Value by Type (2021-2032)
  • 5.3 Global Enfortumab Vedotin‑ejfv Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Enfortumab Vedotin‑ejfv Sales Quantity by Application (2021-2032)
  • 6.2 Global Enfortumab Vedotin‑ejfv Consumption Value by Application (2021-2032)
  • 6.3 Global Enfortumab Vedotin‑ejfv Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Enfortumab Vedotin‑ejfv Sales Quantity by Type (2021-2032)
  • 7.2 North America Enfortumab Vedotin‑ejfv Sales Quantity by Application (2021-2032)
  • 7.3 North America Enfortumab Vedotin‑ejfv Market Size by Country
    • 7.3.1 North America Enfortumab Vedotin‑ejfv Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Enfortumab Vedotin‑ejfv Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Enfortumab Vedotin‑ejfv Sales Quantity by Type (2021-2032)
  • 8.2 Europe Enfortumab Vedotin‑ejfv Sales Quantity by Application (2021-2032)
  • 8.3 Europe Enfortumab Vedotin‑ejfv Market Size by Country
    • 8.3.1 Europe Enfortumab Vedotin‑ejfv Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Enfortumab Vedotin‑ejfv Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Enfortumab Vedotin‑ejfv Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Enfortumab Vedotin‑ejfv Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Enfortumab Vedotin‑ejfv Market Size by Region
    • 9.3.1 Asia-Pacific Enfortumab Vedotin‑ejfv Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Enfortumab Vedotin‑ejfv Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Enfortumab Vedotin‑ejfv Sales Quantity by Type (2021-2032)
  • 10.2 South America Enfortumab Vedotin‑ejfv Sales Quantity by Application (2021-2032)
  • 10.3 South America Enfortumab Vedotin‑ejfv Market Size by Country
    • 10.3.1 South America Enfortumab Vedotin‑ejfv Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Enfortumab Vedotin‑ejfv Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Enfortumab Vedotin‑ejfv Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Enfortumab Vedotin‑ejfv Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Enfortumab Vedotin‑ejfv Market Size by Country
    • 11.3.1 Middle East & Africa Enfortumab Vedotin‑ejfv Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Enfortumab Vedotin‑ejfv Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Enfortumab Vedotin‑ejfv Market Drivers
  • 12.2 Enfortumab Vedotin‑ejfv Market Restraints
  • 12.3 Enfortumab Vedotin‑ejfv Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Enfortumab Vedotin‑ejfv and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Enfortumab Vedotin‑ejfv
  • 13.3 Enfortumab Vedotin‑ejfv Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Enfortumab Vedotin‑ejfv Typical Distributors
  • 14.3 Enfortumab Vedotin‑ejfv Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Enfortumab Vedotin‑ejfv market size was valued at US$ 1996 million in 2025 and is forecast to a readjusted size of US$ 5424 million by 2032 with a CAGR of 13.5% during review period.
    Vandetanib is an oral small molecule tyrosine kinase inhibitor primarily used for the treatment of medullary thyroid cancer (MTC). It works by inhibiting multiple tyrosine kinases associated with cancer cell growth and metastasis, such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and the RET proto-oncogene, thereby suppressing tumor growth and angiogenesis, leading to an anti-tumor effect. Vandetanib can be used alone or in combination with other therapeutic regimens and has shown significant efficacy in the treatment of advanced or metastatic MTC. This drug is typically used in cancer patients whose disease cannot be controlled by conventional therapies and has been approved for clinical use in certain countries and regions.In 2025, global Vandetanib production reached approximately 450,000 bottles.
    Vandetanib (Vandetanib) is a tyrosine kinase inhibitor primarily used to treat medullary thyroid cancer (MTC). With the growing global demand for cancer treatments, particularly in the field of advanced and metastatic cancer treatment, the market prospects for Vandetanib remain promising. In recent years, the diagnostic rate of medullary thyroid cancer has increased, and the limitations of traditional treatments in controlling advanced MTC have led to the gradual emergence of targeted drugs like Vandetanib as a new treatment option.The market demand for Vandetanib primarily comes from MTC patients, especially those for whom traditional therapies are ineffective or surgery cannot be used. Although the drug has been approved and entered markets in certain countries and regions, its high cost and market competition have limited its market penetration. With the rapid development of targeted therapies and the emergence of new-generation cancer drugs, Vandetanib faces intense competition from other treatment options, such as immunotherapies and molecular targeted drugs.
    This report is a detailed and comprehensive analysis for global Enfortumab Vedotin‑ejfv market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Enfortumab Vedotin‑ejfv market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Enfortumab Vedotin‑ejfv market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Enfortumab Vedotin‑ejfv market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Enfortumab Vedotin‑ejfv market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Enfortumab Vedotin‑ejfv
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Enfortumab Vedotin‑ejfv market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Manus Aktteva Biopharma LLP, Apicore Pharmaceuticals, GLR Innovations, Archerchem Healthcare, CLEARSYNTH LABS, SynZeal Research, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Enfortumab Vedotin‑ejfv market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    100 mg
    300 mg
    Market segment by Combination Therapy
    Enfortumab vedotin + Pembrolizumab
    Enfortumab vedotin + platinum-based chemotherapy
    Market segment by Sales Channel
    Hospital
    Retail
    Online
    Market segment by Application
    Advanced Urothelial Cancer
    Advanced Medullary Thyroid Cancer (MTC)
    Others
    Major players covered
    Sanofi
    Manus Aktteva Biopharma LLP
    Apicore Pharmaceuticals
    GLR Innovations
    Archerchem Healthcare
    CLEARSYNTH LABS
    SynZeal Research
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Enfortumab Vedotin‑ejfv product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Enfortumab Vedotin‑ejfv, with price, sales quantity, revenue, and global market share of Enfortumab Vedotin‑ejfv from 2021 to 2026.
    Chapter 3, the Enfortumab Vedotin‑ejfv competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Enfortumab Vedotin‑ejfv breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Enfortumab Vedotin‑ejfv market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Enfortumab Vedotin‑ejfv.
    Chapter 14 and 15, to describe Enfortumab Vedotin‑ejfv sales channel, distributors, customers, research findings and conclusion.

    Buy now